Cross-Sector entity

Johns Hopkins University

Company
6.6

Johns Hopkins University is most often covered alongside Donald Trump, which appears in 5 of these 8 stories. Across a 13-day span, the pace is roughly 4.3 stories per week. The busiest single day carried 5. regulation accounts for 2 of the 8 tracked stories, while 6 other categories carry the remainder.

8 verified stories tracked

Last mentioned: 4d ago

Entity pulse

Recent coverage · Johns Hopkins University

8 stories
6.6 avg impact
38% positive
38% negative

Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.

  • 38% positive
  • 25% neutral
  • 38% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Johns Hopkins University

Johns Hopkins University is most often covered alongside Donald Trump, which appears in 5 of these 8 stories. Across a 13-day span, the pace is roughly 4.3 stories per week. The busiest single day carried 5. regulation accounts for 2 of the 8 tracked stories, while 6 other categories carry the remainder. Each carries 3.1 original sources on average. Negative sentiment appears in 38% of the tracked stories. This profile follows 8 Cross-Sector stories mentioning Johns Hopkins University across the period from August 8, 2026 to August 20, 2026.

Stories tracked
8
Per week
4.3
Negative
38%
Sources per story
3.1

Computed from the 8 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Johns Hopkins University. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Two-week audit deadline

    Affected universities must complete the review and eliminate arrangements considered a national security issue by this date, based on the Pentagon's announced two-week window from August 19.

  2. Trump announces Heidi Overton as FDA Commissioner nominee

    President Trump names the White House Domestic Policy Council deputy director to lead the FDA, pending Senate confirmation.

  3. Pentagon orders 30 universities to audit China ties

    The Department of Defense directed 30 U.S. universities to review partnerships with Chinese universities and military training institutions, with a two-week deadline to eliminate problematic arrangements or face loss of funding.

  4. Pentagon updates list of 130 foreign organizations

    The Defense Department released an updated list of 130 foreign organizations allegedly involved in activities that increase the likelihood of U.S. government-funded research and development being misappropriated.

  5. Marty Makary resigns as FDA Commissioner

    The previous FDA head leaves behind unfinished projects on ultraprocessed foods, antidepressants, and COVID-19 shots.

Stories mentioning Johns Hopkins University 8

Space & Defense geopolitics Negative 7

Pentagon Threatens Funding for 30 Universities in China Crackdown

The Defense Department's audit order targets university research pipelines that feed aerospace and defense technology, potentially disrupting dual-use research in AI, quantum, and space systems. Defense contractors and research universities with Chinese collaborations face a sharper compliance environment.

5 sources
Legal regulation Negative 7

30 Universities Face Pentagon Funding Threat Over China Ties

The Pentagon's order raises due-process, administrative law, and academic-freedom questions, as unnamed institutions face potential funding loss without a clear public standard. The parallel DOJ scholarship probe adds civil-rights and foreign-influence dimensions for university counsel.

5 sources
Healthcare regulation Neutral 7

Overton's FDA Pick: 3 Regulatory Fault Lines for Health Tech

For health IT, medical device and telehealth leaders, Overton's nomination signals a period of regulatory uncertainty. Her backing of MAHA and most favored nation drug pricing could reshape digital health evidence standards, diagnostics oversight and vaccine-adjacent software, even as deregulatory forces promise faster approvals. Confirmation will test how the FDA balances innovation with public health safeguards.

2 sources
Biotech fda approval Neutral 7

Overton FDA Nomination: 4 Biopharma Risks From Drug Pricing to Vaccines

For biotech and pharma executives, Overton's nomination combines Trump's favored-nation drug pricing push with RFK Jr.'s vaccine skepticism and unfinished reviews of antidepressants and COVID shots. The result could compress margins while opening faster approval pathways for innovation. Investors should watch how she navigates evidence standards and political priorities at the FDA.

2 sources

Source: MedPage Today · Kstp Television